Use of proton-pump inhibitors predicts heart failure and death in patients with coronary artery disease by Pello, Ana María et al.
RESEARCH ARTICLE
Use of Proton-Pump Inhibitors Predicts Heart
Failure and Death in Patients with Coronary
Artery Disease
Ana Marı´a Pello La´zaro1*, Carmen Cristo´bal2,3, Juan Antonio Franco-Pela´ez1,
Nieves Tarı´n4, A´ lvaro Aceña1, Rocı´o Carda1, Ana Huelmos5, Marı´a Luisa Martı´n-Mariscal1,
Jesu´s Fuentes-Antras1, Juan Martı´nez-Milla´1, Joaquı´n Alonso3,6, O´ scar Lorenzo7,8,
Jesu´s Egido7,8,9, Lorenzo Lo´pez-Besco´s3, Jose´ Tuño´n1,7,8
1 Department of Cardiology, IIS-Fundacio´n Jime´nez Dı´az, Madrid, Spain, 2 Department of Cardiology,
Hospital de Fuenlabrada, Madrid, Spain, 3 Rey Juan Carlos University, Alcorco´n, Madrid, Spain,
4 Department of Cardiology, Hospital Universitario de Mo´stoles, Madrid, Spain, 5 Department of Cardiology,
Hospital Universitario Fundacio´n Alcorco´n, Madrid, Spain, 6 Department of Cardiology, Hospital de Getafe,
Madrid, Spain, 7 Auto´noma University, Madrid, Spain, 8 Laboratory of Vascular Pathology, IIS-Fundacio´n




Proton-pump inhibitors (PPIs) seem to increase the incidence of cardiovascular events in
patients with coronary artery disease (CAD), mainly in those using clopidogrel. We analysed
the impact of PPIs on the prognosis of patients with stable CAD.
Methods
We followed 706 patients with CAD. Primary outcome was the combination of secondary
outcomes. Secondary outcomes were 1) acute ischaemic events (any acute coronary syn-
drome, stroke, or transient ischaemic attack) and 2) heart failure (HF) or death.
Results
Patients on PPIs were older [62.0 (53.0–73.0) vs. 58.0 (50.0–70.0) years; p = 0.003] and
had a more frequent history of stroke (4.9% vs. 1.1%; p = 0.004) than those from the non-
PPI group, and presented no differences in any other clinical variable, including cardiovas-
cular risk factors, ejection fraction, and therapy with aspirin and clopidogrel. Follow-up was
2.2±0.99 years. Seventy-eight patients met the primary outcome, 53 developed acute
ischaemic events, and 33 HF or death. PPI use was an independent predictor of the primary
outcome [hazard ratio (HR) = 2.281 (1.244–4.183); p = 0.008], along with hypertension,
body-mass index, glomerular filtration rate, atrial fibrillation, and nitrate use. PPI use was
also an independent predictor of HF/death [HR = 5.713 (1.628–20.043); p = 0.007], but not
of acute ischaemic events. A propensity score showed similar results.
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Conclusions
In patients with CAD, PPI use is independently associated with an increased incidence of
HF and death but not with a high rate of acute ischaemic events. Further studies are needed
to confirm these findings.
Introduction
The efficacy of proton-pump inhibitors (PPIs) in suppressing gastric acid secretion has led
them to be preferred over other drugs such as histamine H2 receptor antagonists [1].
In patients with coronary artery disease (CAD), aspirin is used to decrease the incidence of
cardiovascular events, and in patients who have undergone stent placement or have suffered
an acute coronary syndrome, a P2Y12 receptor blocker such as clopidogrel is added. These anti-
platelet agents, however, may favour the development of gastrointestinal (GI) complications.
Prolonged aspirin therapy is associated with GI ulceration and bleeding, which have been
attributed to mucosal injury caused by inhibition of prostaglandin and to systemic inhibition
of thromboxane A2 production, respectively. In addition, clopidogrel may impair the healing
of gastric erosions, exacerbating GI complications associated with the concomitant adminis-
tration of aspirin [2].
PPIs are indicated in CAD patients to decrease the risk of upper GI haemorrhage due to
antiplatelet therapy [3]. However, patients treated with PPIs may develop osteoporosis-related
fractures [4], pneumonia, Clostridium difficile infection, acute interstitial nephritis, and micro-
nutrient deficiencies [5,6]. In addition, it has been suggested that PPIs may increase the inci-
dence of cardiovascular events in CAD patients by decreasing the effect of aspirin—and,
mainly, clopidogrel—on platelet aggregation [7–11]. Although several pharmacodynamic
studies have suggested an interaction between PPIs and antiplatelet drugs [12], clinical studies
have shown divergent results [13,14].
In this study we assessed the potential association between the use of PPIs and adverse out-




The research protocol complies with the Declaration of Helsinki and was approved by the eth-
ics committees of the participating hospitals. All patients included in the study signed
informed consent documents. As described in detail previously, the BACS & BAMI (Biomark-
ers in Acute Coronary Syndrome & Biomarkers in Acute Myocardial Infarction) studies
included patients admitted to 4 hospitals in Madrid with either non-ST elevation acute coro-
nary syndrome (NSTEACS) or ST elevation myocardial infarction (STEMI) [15]. Detailed
inclusion and exclusion criteria have been previously reported [15,16]. Patients were seen on
an outpatient basis 6 months after initial diagnosis. At this time plasma was withdrawn and a
complete set of clinical variables was recorded. At this outpatient visit we started a prospective
follow-up relating the clinical and analytical findings obtained with the outcome of the
patients.
Between July 2006 and April 2010, 1,898 patients were discharged from the study hospitals
with a diagnosis of NSTEACS or STEMI [15]. Of these, 838 were eventually included in the
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study [15]. The remaining patients were not included based on the following exclusion crite-
ria, that have been described previously [15,16]: age over 85 years (17.3%), disorders limiting
survival (29.0%), impossibility to perform cardiac revascularisation (14.5%), coexistence of
other significant cardiac disorders (6.8%), impossibility to perform follow-up (12.0%), clini-
cal instability beyond the sixth day at the index event (9.1%), refusal to participate in the
study (2.0%), and impossibility of the investigators to include them (9.3%). Of the 838
patients included during the acute event, 711 attended the outpatient visit at 6 months and
had adequate plasma samples stored. This visit took place between January 2007 and Febru-
ary 2011. Final follow-up visits took place in May 2012. Five patients were lost to follow-up,
leaving a total of 706 patients for analysis.
Study Design
As explained previously, at baseline, clinical variables were recorded and twelve-hour fasting
venous blood samples were withdrawn and collected in EDTA. Blood samples were centri-
fuged at 2,500 g for 10 minutes and plasma was stored at –80˚C. Patients were seen every year
at their hospital. At the end of follow-up (maximum 4.6 years) medical records were reviewed
and patient status was confirmed by telephone contact.
The primary outcome was the composite of the secondary end points. The secondary out-
comes were 1) recurrence of acute ischaemic events such as NSTEACS, STEMI, stroke, or
transient ischaemic attack, and 2) incidence of heart failure (HF) or death from any cause.
NSTEACS was defined as rest angina lasting more than 20 minutes in the previous 24 hours or
new-onset class III-IV angina, along with transient ST-segment depression or T-wave inver-
sion in the electrocardiogram considered diagnostic by the attending cardiologist and/or tro-
ponin elevation. STEMI was defined as symptoms compatible with angina lasting more than
20 minutes and ST elevation in 2 adjacent leads in the electrocardiogram without response to
nitroglycerin, and troponin elevation. Stroke was defined as rapid onset of a persistent neuro-
logic deficit attributable to a focal vascular cause and lasting more than 24 hours, supported in
most cases by imaging studies. A transient ischaemic attack was defined as a stroke with signs
and symptoms resolving before 24 hours without acute ischaemic lesions as assessed by imag-
ing studies. The HF end point was assigned to patients hospitalised for this reason. Events
were adjudicated by 2 investigators. Cerebrovascular events were adjudicated with the assis-
tance of a neurologist.
Analytical Studies
Laboratory analyses were carried out in the Clinical Biochemistry Laboratory of the IIS-Fun-
dacio´n Jime´nez Dı´az by investigators who were unaware of the clinical data. As in previous
papers studying this population, high-sensitivity C-reactive protein was determined by latex-
enhanced immunoturbidimetry (ADVIA 2400 Chemistry System, Siemens, Germany) [15].
Lipid, glucose, and creatinine determinations were carried out by standard methods (ADVIA
2400 Chemistry System, Siemens, Germany) [15].
Statistical Analysis
Quantitative data following a normal distribution are presented as mean ± standard deviation
and compared using the Student “t” test. Data that were not normally distributed are displayed
as median (interquartile range) and compared using the Mann-Whitney test. Qualitative vari-
ables are displayed as percentages and were compared by χ2 or Fisher exact test when appro-
priate. Kaplan-Meier curves and the log-rank test were used to compare time to outcome
according to therapy with PPIs. Cox proportional hazards modelling was used with forward
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stepwise selection to assess the variables associated with the primary and secondary outcomes.
In model 1, clinical and analytical variables were studied: age, sex, diabetes, smoking status,
hypertension, body-mass index, LDL, HDL, triglycerides, previous history of peripheral artery
disease, cerebrovascular events, atrial fibrillation or coronary artery by-pass graft; ejection
fraction<40%, glomerular filtration rate assessed as Chronic Kidney Disease Epidemiology
Collaboration method (CKD-EPI), high-sensitivity C-reactive protein, type of last acute coro-
nary event, number of diseased vessels, percutaneous or surgical revascularisation, use of
drug-eluting stents and existence of complete revascularisation at that event. In model 2, treat-
ment with PPIs and other therapies were added: aspirin, clopidogrel, statins, acenocumarol,
angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, betablockers,
nitrates/nitroglycerin and diuretics. We considered significant when “p” value was lower than
0.05 (two-tailed). Analyses were carried out with SPSS 19.0 (SPSS Inc., New York).
A propensity score adjustment was performed using a multivariable logistic regression
model in 2 steps, including clinical variables in the first one and adding the therapies used in
the second step.
Summary of the Study
In conclusion, in this study we have followed 706 patients with chronic CAD, assessing the
potential relationship of PPI use with the development of acute ischaemic events, heart failure
(HF), or death.
Results
Mean follow-up was 2.2±0.99 years. Time from the previous acute coronary event was 7.5 ±
3.0 months.
Of the 706 patients analysed, 431 (61.04%) were receiving PPIs. Most of them (405 patients,
(57.4%)) were taking omeprazole, 19 (2.7%) pantoprazole, 6 (0.8%) lansoprazole, and 1 patient
(0.1%) was taking rabeprazole. There were 72 (10.2%) patients treated with histamine H2
receptor antagonists, and the remaining patients did not receive gastric protectors. Patients
receiving these drugs were older and had a more frequent history of cerebrovascular events
than those not receiving them. No differences were observed in cardiovascular therapy or any
other clinical or analytical variables (Table 1).
Seventy-eight patients developed the primary outcome of acute ischaemic events, HF, or
death. Sixty-three (14.61%) patients taking PPIs and 15 (5.45%) not on PPIs met this outcome.
Twelve patients developed 2 events, 5 patients experienced 3 events and, the remainder, one
event with a total of 100 events. At multivariable analysis we included the variables displayed
in Table 1 in two models, as described in the Methods section. PPI use was an independent
predictor of the primary outcome, along with hypertension, age, body-mass index, estimated
glomerular filtration rate, atrial fibrillation, and nitrate use (Table 2). The interaction between
PPIs and clopidogrel did not reach statistical significance (p = 0.463).
When multivariable Cox regression analysis was performed comparing patients with ome-
prazol with those no taking this drug (then including 26 patients using other PPIs in this
group) omeprazol was an independent risk predictor (HR 2.343 [1.320–4.158]; p = 0.004)
along with hypertension (HR 2.591 [1.262–5.321]; p = 0.010), body-mass index (HR 1.060
[1.006–1.116]; p = 0.028), atrial fibrillation (HR 2.561 [1.372–4.781]; p = 0.003), glomerular fil-
tration rate (HR 0.975 [0.963–0.987]; p<0.001), and use of nitrates (HR 2.678 [1.626–4.404];
p<0.001). Comparing patients with omeprazol with the remaining cases not on PPIs con-
firmed that omeprazol (HR 2.371 [1.290–4.358]; p = 0.005) was an independent predictor of
the primary outcome along with the same other described variables. Given that the number of
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cases on anti-H2 and without gastric protectors was very low it was not possible to perform
other comparisons.
Fifty-three patients developed acute ischaemic events. Forty-two (9.74%) of the patients on
PPIs and 11 (4%) of those not receiving these drugs met this end point. There were 4 episodes
of STEMI, 22 of NSTEACS, 17 of unstable angina, 8 strokes, and 10 transient ischaemic
attacks. Four patients experienced 2 events and 2 patients experienced 3 events. By
Table 1. Characteristics of patients with and without treatment with proton-pump inhibitors.
Patients receiving PPIs (N = 431) Patients not receiving PPIs (N = 275) P Value
Age, y 62.0 (53.0–73.0) 58.0 (50.0–70.0) 0.003
Male sex (%) 74.5 76.4 0.593
Caucasian (%) 97.9 95.6 0.110
Body-mass index (Kg/m2) 28.7±4.4 28.8±4.7 0.861
Diabetes (%) 22.7 24.0 0.715
Present smoker (%) 5.6 8.0 0.213
Hypertension (%) 66.8 62.5 0.257
Peripheral artery disease (%) 3.9 3.6 1.000
Cerebrovascular events (%) 4.9 1.1 0.004
Previous CABG (%) 9.3 6.9 0.329
Atrial fibrillation (%) 3.5 1.6 0.381
Ejection fraction < 40% (%) 11.8 12.0 0.725
MEDICAL THERAPY
Aspirin (%) 91.4 92.7 0.573
Clopidogrel (%) 66.8 69.1 0.564
Acenocoumarol (%) 6.7 5.1 0.423
Statins (%) 87.5 87.6 1.000
ACEI (%) 55.9 54.2 0.698
ARB (%) 17.4 14.9 0.406
Betablockers (%) 74.2 79.6 0.103
Nitrates/Nitroglycerin (%) 17.2 16.7 0.918
Diuretics (%) 21.8 16.0 0.064
DATA FROM LAST ACUTE CORONARY EVENT
STEMI/NSTEACS (%) 39.9/60.1 36.7/63.3 0.428
Number of vessels diseased 1.39±0.79 1.35±0.83 0.517
Complete revascularisation (%) 6.3 4.7 0.410
Drug-eluting stent (%) 44.5 50.9 0.105
PCI (%) 74.0 73.5 0.930
CABG (%) 6.3 4.7 0.384
ANALYTICAL DATA
LDL cholesterol (mg/dl) 84.3±26.4 81.4±24.3 0.149
HDL cholesterol (mg/dl) 43.7±10.6 44.1±11.4 0.683
Triglycerides (mg/dl) 129.7±71.3 132.7±98.3 0.640
GFR (ml/min/1.73 m2) 75.7±21.7 76.5±18.6 0.600
HS C-reactive protein (mg/L) 4.66±10.39 4.24±8.38 0.569
ACEI: angiotensin-converting enzyme inhibitors; ACS: acute coronary syndrome; ARB: angiotensin receptor blockers; CABG: coronary artery by-pass
graft; GFR: glomerular filtration rate (Chronic Kidney Disease Epidemiology Collaboration method); HDL: high-density lipoprotein; HS: high-sensitivity;
LDL: low-density lipoprotein; NSTEACS: Non-ST elevation acute coronary syndrome; PCI: percutaneous coronary intervention; PPIs: Proton-Pump
Inhibitors; STEMI: ST-elevation myocardial infarction
doi:10.1371/journal.pone.0169826.t001
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multivariable analysis, age, body-mass index, and treatment with nitrates, but not with PPIs,
were independent predictors of this end point (Table 3).
Thirty-three patients developed HF or death. This end point was met by 28 patients (6.49%)
on PPIs, and by 5 patients (1.81%) not receiving this therapy. There were 16 episodes of HF
and 23 deaths, with 6 patients experiencing 2 events. Nine deaths were due to cardiovascular
causes (3 of them were sudden death) and 4 were due to malignancies. Infection, renal failure,
bowel ischaemia, GI bleeding, and pancreatitis accounted for 1 death each. Five deaths were
of unknown cause. Therapy with PPIs was also an independent predictor of this outcome
(Table 4).
Table 2. Cox proportional hazards model for the incidence of primary outcome: acute ischaemic events, heart failure, or death.
Model 1 Model 2
Hazard Ratio 95% CI P value Hazard Ratio 95% CI P value
Lower Upper Lower Upper
Hypertension 2.271 1.106 4.665 0.025 2.529 1.232 5.195 0.011
Atrial fibrillation 2.102 1.111 3.977 0.022 2.598 1.390 4.854 0.003
Agea 1.036 1.008 1.064 0.011 --- --- --- ---
BMIb 1.074 1.020 1.131 0.007 1.060 1.006 1.116 0.029
CKD-EPIc 0.982 0.967 0.997 0.021 0.974 0.962 0.987 <0.001
Nitrates --- --- --- --- 2.669 1.626 4.378 <0.001
PPIs --- --- --- --- 2.281 1.244 4.183 0.008
Model 1: Risk adjusted for age, sex, diabetes, smoking status, hypertension, body-mass index, low-density lipoprotein, high-density lipoprotein, and
triglyceride plasma levels; previous history of peripheral artery disease, cerebrovascular events, atrial fibrillation or coronary artery by-pass graft; ejection
fraction <40%, glomerular filtration rate assessed as Chronic Kidney Disease Epidemiology Collaboration method, high-sensitivity C-reactive protein; type
of last acute coronary event, number of diseased vessels, percutaneous or surgical revascularisation, use of drug-eluting stents and existence of complete
revascularisation at that event.
Model 2: Risk adjusted for factors in model 1 plus therapy with proton-pump inhibitors, aspirin, clopidogrel, statins, acenocoumarol, angiotensin-converting
enzyme inhibitors, angiotensin receptor blockers, betablockers, diuretics and nitrates/nitroglycerin.
BMI: body-mass index; CI: confidence interval; CKD-EPI: glomerular filtration rate assessed according to the Chronic Kidney Disease Epidemiology
Collaboration method; PPIs: proton-pump inhibitors.
a: hazard ratio estimated by every increase of 1 year.
b: hazard ratio estimated by every increase of 1 kg/m2.
c: hazard ratio estimated by every increase of 1 ml/min/1.73m2
doi:10.1371/journal.pone.0169826.t002
Table 3. Cox proportional hazards model for the incidence of acute ischaemic events.
Model 1 Model 2
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Lower Upper Lower Upper
Agea 1.045 1.015 1.065 <0.001 1.042 1.017 1.068 0.001
BMIb 1.105 1.044 1.169 0.001 1.105 1.045 1.169 0.001
Nitrates --- --- --- --- 1.882 1.005 3.525 0.048
Models 1 and 2 as described in Table 2
BMI: body-mass Index; CI: confidence interval
a: Hazard ratio estimated by every increase of 1 year.
b: Hazard ratio estimated by every increase of 1 kg/m2.
doi:10.1371/journal.pone.0169826.t003
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Kaplan-Meier curves showed that patients on PPIs developed more often the primary out-
come (p = 0.013; log-rank test) (Fig 1A) and a borderline “p” value (p = 0.050) for the second-
ary outcome of heart failure or death (Fig 1B).
Finally, we performed a propensity score analysis. In the first step, we included clinical vari-
ables, and treatment with PPIs significantly increased the incidence of the primary outcome
(HR = 1.912, [95% CI = 1.037–3.523]; p = 0.028). The combined outcome of HF or death
showed a result in the limit of statistical significance (HR = 2.921, [95% CI = 0.867–9.840];
p = 0.050). In the second step, we added concomitant drug therapy, showing that PPI treat-
ment increased the incidence of the primary outcome (HR = 1.938, 95% CI = 1.050 to 3.576,
p = 0.025), although the combination of HF or death lost the statistical significance (HR =
2.767, 95% CI = 0.817 to 9.373, p = 0.066).
Discussion
It has been suggested that treatment with PPIs are associated with an increased incidence of
cardiovascular events in patients with CAD, mainly in those receiving clopidogrel [14].
In the present study, PPI treatment in patients with CAD was associated with a significant
increase in the incidence of HF or death. The distribution of clinical and analytical variables
across patients taking PPIs was similar to that of patients not taking these drugs, though with 2
exceptions. First, patients on PPIs were older. This is logical, since age is a risk factor for GI
bleeding [17]. Second, patients receiving PPIs had a more frequent history of cerebrovascular
events. Although the rate of anticoagulation in these patients was slightly higher than in those
not on PPIs, this difference did not reach statistical significance. Moreover, these factors were
included in a multivariable analysis, and PPI treatment remained an independent predictor of
adverse events. The only exception was the fully adjusted propensity score for the development
Table 4. Cox proportional hazards model for the incidence of heart failure or death.
Model 1 Model 2
Hazard ratio 95% CI P value Hazard ratio 95% CI P value
Lower Upper Lower Upper
Atrial fibrillation 3.531 1.508 8.270 0.004 6.884 2.788 16.999 <0.001
Diabetes 0.607 0.416 0.885 0.010 --- --- --- ---
Agea 1.062 1.011 1.115 0.016 --- --- --- ---
CKD-EPIb 0.958 0.933 0.983 0.001 0.951 0.932 0.971 <0.001
Previous PCI 1.522 1.040 2.227 0.031 --- --- --- ---
Hypertension --- --- --- --- 6.443 0.852 48.696 0.071*
Nitrates --- --- --- --- 4.554 2.135 9.713 <0.001
PPIs --- --- --- --- 5.713 1.628 20.043 0.007
Peripheral artery disease --- --- --- --- 0.466 0.250 0.869 0.016
LDL --- --- --- --- 0.983 0.966 1.000 0.045
Models 1 and 2 as described in Table 2
CI: confidence interval; CKD-EPI: glomerular filtration rate assessed as Chronic Kidney Disease Epidemiology Collaboration method; LDL: low-density
lipoprotein; PCI: percutaneous coronary intervention; PPIs: proton-pump inhibitors
* Although this P value failed to reach statistical significance, this variable was maintained in the model because the P value calculated with the likelihood
ratio method was 0.015
a: Hazard ratio estimated by every increase of 1 year.
b: Hazard ratio estimated by every increase of 1 ml/min/1.73m2
doi:10.1371/journal.pone.0169826.t004
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Fig 1. Kaplan-Meier curves showing time to the outcomes in patients with or without PPIs. (A) Time to
primary outcome (acute ischaemic events, heart failure or death). (B) Time to heart failure or death. (C) Time
to acute ischaemic events.
doi:10.1371/journal.pone.0169826.g001
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of HF or death, which lost significance, likely due to the limited number of patients presenting
this outcome.
More than 90% of patients were taking aspirin. Chronic treatment with aspirin is a risk fac-
tor for GI bleeding regardless of the dose used [18]. Furthermore, two-thirds of the patients
were treated also with clopidogrel, and no differences were observed between the PPI and
non-PPI groups for this variable. Of interest, no significant interaction was found between clo-
pidogrel use and the association of PPI administration with the primary outcome. Moreover,
none of our patients was taking prasugrel or ticagrelor, since at the time this investigation was
performed only clopidogrel was available in the participating hospitals.
The present work shows that PPI use is an independent predictor of HF or death. Although
there are no previous studies reporting this association, it is known that pantoprazole may
exert negative inotropic effects on isolated myocardium from humans and rabbits [19]. This
effect was dose-dependent and partially reversible. PPIs decrease gastric acid secretion by
blocking the gastric acid pump H-/K+-adenosine triphosphatase (ATPase). This pump is also
present in the myocardium of rats [20]. Inhibition of H-/K+ ATPase might therefore induce
cellular acidosis and a secondary depression in myocardial contractility. However, this was not
the mechanism of action of pantoprazole, as no significant changes in intracellular pH could
be detected, and all effects occurred at pH 7.3–7.4. Two underlying mechanisms for the panto-
prazole-dependent inhibition of contractile force have been described [19]: (1) a decrease in
the amplitude of Ca2+ transients due to an impaired sarcoplasmic reticulum Ca2+ uptake and
diminished Ca2+ influx via I Ca L, and (2) reduced Ca2+ responsiveness of the myofilaments as
a consequence of decreased maximal active tension and mildly lower Ca2+ sensitivity. Similar
results have been obtained with esomeprazole [19] and omeprazole [21], suggesting a class
effect.
Although the findings from laboratory studies have been promising, there is controversy
regarding the clinical effects of PPIs on myocardial function. Using echocardiography, Schil-
linger et al did not observe any effect of high doses of intravenous pantoprazole on left ventric-
ular ejection fraction or several hemodynamic parameters in healthy volunteers [22]. On the
other hand, Tanaka et al showed that chronic administration of PPIs in patients with stable
angina could be associated with a decrease in ejection fraction and an increase in end-systolic
volume index [23].
The increase in mortality associated with PPI use described in the present paper is consis-
tent with previous data. The use of high doses of PPIs has been associated with increased mor-
tality in 491 older patients discharged from acute care hospitals, even when multivariable
analysis including predictors of adverse outcomes was carried out [5]. Similarly, PPI use was
independently associated with all-cause mortality in 2 cohorts of older patients in long-term
care hospitals, acute geriatric wards, and nursing homes [5,24]. Similar results were seen in
patients discharged from acute care hospitals [25].
Several potential mechanisms have been suggested to explain the relationship between PPIs
and the risk of death [26]. First, the suppression of gastric acidity and the alteration in gut bac-
terial flora may be the cause of the higher prevalence of Clostridium difficile infections and
community-acquired pneumonia described in long-term PPI users [5,27,28]. Second, PPI use
may cause vitamin B12 deficiency, thus leading to a poor nutritional status [29]. In fact, abol-
ishing acid production may interfere with the absorption of nutrients, enhancing the risk of
malnutrition [30]. Third, the U.S. Food and Drug Administration reported in 2011 that pre-
scription of PPI drugs for prolonged periods could cause hypomagnesaemia. The mechanism
responsible is unknown but may be associated with changes in intestinal absorption of magne-
sium. Hypomagnesaemia also produces impaired parathyroid hormone secretion, which may
lead to hypocalcaemia. Furthermore, as the intracellular concentration of magnesium is
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involved in the regulation of potassium channels, low magnesium levels may lead to urinary
potassium excretion and subsequent hypokalaemia [31,32]. Then, these electrolyte distur-
bances could cause both supraventricular and ventricular arrhythmias with cardiac arrest or
death [33,34]. Nevertheless, future investigations with larger populations are needed to at least
confirm a relationship between PPI use and the occurrence of sudden death. Finally, a higher
risk of bone fractures has been described in older people taking PPIs [35]. Although the cause
of death was available in our patients, the number of specific events for each cause was too
small to obtain a reliable estimate of the association between the use of PPIs and each specific
cause of death.
In contrast to our data, Oudit et al found that PPI use was not associated with all-cause
mortality in a cohort of 22,107 patients over age 65 with HF [36]. However, they had a different
profile from that of our study, including older age, more comorbidities, and higher mortality.
Use of PPIs was not an independent predictor of acute ischaemic events. Pharmacokinetic
and pharmacodynamic studies suggest that use of PPIs may reduce the antiplatelet effects of
clopidogrel. The strongest evidence for such an interaction has been found between omepra-
zole and clopidogrel [37,38]. Ho et al reported an increased incidence of hospitalisation for
acute coronary syndromes or death in patients with acute coronary syndrome receiving clopi-
dogrel and PPIs [14]. However, recent retrospective studies including propensity score match-
ing have not confirmed these data [39]. In addition, the only randomised double-blinded trial
available compared omeprazole and placebo in 3,873 patients with indication for dual anti-
platelet therapy, and did not find more adverse cardiovascular events in the PPI group [3].
However, this trial was terminated before schedule and the number of events was lower than
expected. In our study there were no differences in the use of aspirin and clopidogrel in PPIs
users vs. non-users. What is more, treatment with clopidogrel did not affect the association
between therapy with PPIs and the incidence of the primary outcome. It therefore seems rea-
sonable to conclude that PPIs had no effect on the incidence of acute ischaemic events and
that clopidogrel use did not affect the association observed with the primary outcome.
Finally, we were unable to explore whether adverse prognosis was associated with all PPIs
or only with omeprazol, given that the number of patients with other PPIs was low. Similarly,
our study did not allow us to analyse whether the adverse effect of PPIs was evident only when
comparing these patients to those taking antiH2 or, alternatively, if this effect was also present
when comparing PPI patients with those receiving no gastric protectors. The reason for this is
that, in accordance with the current clinical practice, the number of patients without any gas-
tric protector was very low.
This work has certain limitations. First, this is a non-randomised study with some signifi-
cant differences at baseline between patients receiving PPI and those who did not. Although
we included these variables in the multivariate and propensity score analysis, the small sample
size may have limited the statistical power. Second, excluding patients with clinical instability
in the first days after the index event may have introduced a bias, as these patients would prob-
ably have evidenced a worse prognosis. Nevertheless, only 9 percent of cases were excluded for
this reason and the remaining exclusion criteria were designed to prevent the inclusion of
cases that could have yielded confounding information, such as patients with major additional
disorders. Third, the number of total events was small, thus limiting the strength of the statisti-
cal analysis. Fourth, there were few deaths, making it impossible to test whether there was an
association between use of PPIs and some specific cause of death. Fifth, the study quality is
modest, as more than 50% of patients discharged from the hospitals with a diagnosis of
NSTEACS or STEMI were not included in the study based on the exclusion criteria described
in the Methods section. Finally, adherence to medication regimens during follow-up was not
addressed.
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Conclusions
In conclusion, our results suggest an association between use of PPIs and the incidence of
death or HF but do not point to an association with incidence of acute ischaemic events. More
studies are needed to confirm these data.
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